Physician profile
Thomas S Stanton
NPI 1699855445
$6,585.04
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,091 · 2020: $4,494.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $4,236.24 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $1,440.00 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $115.08 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $109.82 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $68.75 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.42 | 2019-2020 | |
| Genentech USA, INC. | $67.13 | 2019 | |
| Seagen INC. | $54.86 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $46.79 | 2019 | |
| Amgen INC. | $39.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.31 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $37.97 | 2020 | |
| Lilly USA, LLC | $35.90 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $32.88 | 2019 | |
| Eisai INC. | $23.86 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $20.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.46 | 2019 | |
| Jazz Pharmaceuticals INC. | $18.97 | 2019 | |
| Abbvie INC. | $17.63 | 2019 | |
| Karyopharm Therapeutics INC. | $16.82 | 2020 | |
| Astellas Pharma US INC | $16.33 | 2020 | |
| Clovis Oncology, INC. | $15.16 | 2019 | |
| Dendreon Pharmaceuticals LLC | $14.51 | 2019 | |
| Glaxosmithkline, LLC. | $14.29 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.17 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Research and ownership
$2,629.86 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Stanton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.